10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

(Mark One)

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2014

or

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to ____________

Commission File Number: 2-93277-D

MEDIZONE INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

Nevada	87-0412648
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

4000 Bridgeway, Suite 401, Sausalito, California  94965

(Address of principal executive offices, Zip Code)

(415) 331-0303

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes þ No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes þ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨	Accelerated filer ¨
Non-accelerated filer ¨ (Do not check if a smaller reporting company)	Smaller reporting company þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ¨ No þ

As of April 28, 2014, the registrant had 338,105,496 shares of common stock issued and outstanding.

MEDIZONE INTERNATIONAL, INC.

FORM 10-Q

TABLE OF CONTENTS

March 31, 2014

		Page No.
Part I — Financial Information
Item 1.	Financial Statements (Unaudited)	3
	Condensed Consolidated Balance Sheets: March 31, 2014 and December 31, 2013	3
	Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2014 and 2013	4
	Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2014 and 2013	5
	Notes to the Condensed Consolidated Financial Statements	7
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	12
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	14
Item 4.	Controls and Procedures	14
Part II — Other Information
Item 1.	Legal Proceedings	15
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	15
Item 3.	Defaults Upon Senior Securities	15
Item 4.	Mine Safety Disclosures	15
Item 5.	Other Information	15
Item 6.	Exhibits	16
Signatures		17

PART I – FINANCIAL INFORMATION

Item 1.  Financial Statements

MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (Unaudited)

	March 31,				December 31,
	2014				2013
ASSETS
Current Assets:
Cash		$	744,426			$	81,856
Inventory			265,234				265,234
Prepaid expenses			46,092				33,085
Total Current Assets			1,055,752				380,175
Property and equipment, net			1,353				1,616
Other Assets:
Trademark and patents, net			218,781				219,563
Lease deposit			4,272				4,272
Total Other Assets			223,053				223,835
Total Assets		$	1,280,158			$	605,626
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities:
Accounts payable		$	458,299			$	477,563
Accounts payable – related parties			235,047				234,677
Accrued expenses			526,093				522,179
Accrued expenses – related parties			1,928,659				1,928,659
Customer deposits			30,000				30,000
Other payables			224,852				224,852
Notes payable			301,700				295,496
Total Current Liabilities			3,704,650				3,713,426
Commitments and Contingencies (Note 5)
Stockholders’ Deficit:
Preferred stock, $0.00001 par value: 50,000,000 shares authorized;     no shares issued or outstanding			-				-
Common stock, $0.001 par value; 395,000,000 shares authorized;     338,105,496 and 322,055,496 shares outstanding, respectively			338,106				322,055
Additional paid-in capital			29,080,024				28,018,398
Accumulated other comprehensive loss			(25,755	)			(26,269	)
Accumulated deficit			(31,816,867	)			(31,421,984	)
Total Stockholders' Deficit			(2,424,492	)			(3,107,800	)
Total Liabilities and Stockholders’ Deficit		$	1,280,158			$	605,626

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Comprehensive Loss (Unaudited)

	For the Three Months Ended
	March 31,
	2014			2013
Revenues	$	-		$	4,554
Operating Expenses:
Cost of revenues		-			4,000
General and administrative		289,531			285,211
Research and development		87,071			85,771
Depreciation and amortization		11,905			10,504
Total Operating Expenses		388,507			385,486
Loss from Operations		(388,507	)		(380,932	)
Interest expense		(6,376	)		(6,366	)
Net Loss		(394,883	)		(387,298	)
Other comprehensive gain (loss) on foreign currency translation		514			(172	)
Total Comprehensive Loss	$	(394,369	)	$	(387,470	)
Basic and Diluted Net Loss per Common Share	$	(0.00	)	$	(0.00	)
Weighted Average Number of Common Shares Outstanding		324,076,274			295,469,004

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (Unaudited)

	For the Three Months Ended
	March 31,
	2014			2013
Cash Flows from Operating Activities:
Net loss	$	(394,883	)	$	(387,298	)
Adjustments to reconcile net loss to net cash  used in operating activities:
Depreciation and amortization		11,905			10,483
Stock-based compensation		28,427			40,809
Changes in operating assets and liabilities:
Prepaid expenses		14,162			(15,579	)
Customer deposits		-			(4,554	)
Accounts payable and accounts payable – related parties		(18,894	)		45,473
Accrued expenses and accrued expenses – related parties		3,914			6,501
Net Cash Used in Operating Activities		(355,369	)		(304,165	)
Cash Flows from Investing Activities:
Purchase of trademark and patents		(10,860	)		(6,464	)
Net Cash Used in Investing Activities		(10,860	)		(6,464	)
Cash Flows from Financing Activities:
Principal payments on notes payable		(20,965	)		(18,722	)
Issuance of common stock for cash		1,049,250			367,000
Net Cash Provided by Financing Activities		1,028,285			348,278
Effect of Foreign Currency Exchange Rates		514			(172	)
Net increase in cash		662,570			37,477
Cash as of beginning of the period		81,856			12,456
Cash as of end of the period	$	744,426		$	49,933

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (Unaudited) (Continued)

	For the Three Months Ended
	March 31,
SUPPLEMENTAL CASH FLOW INFORMATION:	2014		2013
Cash paid for interest	$	462	$	307
NON-CASH FINANCING ACTIVITIES:
Financing of insurance policies	$	27,169	$	27,250

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

NOTE 1     BASIS OF PRESENTATION

The financial information included herein is unaudited and has been prepared consistent with US generally accepted accounting principles (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all information and notes required by US GAAP for complete financial statements. These notes should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2013. In the opinion of management, these financial statements contain all adjustments (consisting solely of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended March 31, 2014 are not necessarily indicative of the results to be expected for the full year.

NOTE 2     CANADIAN FOUNDATION FOR GLOBAL HEALTH

In late 2008, the Company assisted in the formation of the Canadian Foundation for Global Health (“CFGH”), a not-for-profit foundation based in Ottawa, Canada. The Company helped establish CFGH for two primary purposes: (1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with the Company for research purposes that is best positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit; and (2) to provide a means for the Company to use a tiered pricing structure for services and products in emerging economies and extend the reach of the Company’s technology to as many in need as possible.

Accounting standards require a variable interest entity (“VIE”) to be consolidated by a company if that company absorbs a majority of the VIE’s expected losses and/or receives a majority of the entity’s expected residual returns as a result of holding variable interests, which are the ownership, contractual, or other financial interests in the entity. In addition, a legal entity may be considered to be a VIE, if it does not have sufficient equity at risk to finance its own activities without relying on financial support from other parties. If the legal entity is a VIE, then the reporting entity determined to be the primary beneficiary of the VIE must consolidate its financial statements with those of the VIE. The Company determined that CFGH met the requirements of a VIE effective upon the first advance to CFGH on February 12, 2009. Accordingly, the financial statements of CFGH have been consolidated with those of the Company for all periods presented.

NOTE 3     BASIC AND DILUTED NET LOSS PER COMMON SHARE

The computations of basic and diluted net loss per common share are based on the weighted average number of common shares outstanding during the periods as follows:

	For the Three Months Ended March 31,
	2014			2013
Numerator: Net loss	$	(394,883	)	$	(387,298	)
Denominator: Weighted average number of common shares outstanding		324,076,274			295,469,004
Basic and diluted net loss per common share	$	(0.00	)	$	(0.00	)

Common stock equivalents, consisting of options, have not been included in the calculation as their effect is antidilutive for the periods presented.

NOTE 4     GOING CONCERN

The Company’s consolidated financial statements are prepared using US GAAP applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business.  The Company has incurred significant losses from its inception through March 31, 2014, which have resulted in an accumulated deficit of $31,816,867 as of March 31, 2014.  The Company does not have funds sufficient to cover its operating costs for the next 12 months, has a working capital deficit of $2,648,898, and has relied exclusively on debt and equity financing.  Accordingly, there is substantial doubt about its ability to continue as a going concern.

7

MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

NOTE 4     GOING CONCERN (continued)

Continuation of the Company as a going concern is dependent upon future revenues, obtaining additional capital and ultimately, upon the Company’s attaining profitable operations.  The Company will require substantial additional funds to complete the continued development of its products, product manufacturing, and to fund expected additional losses, until revenues are sufficient to cover the Company’s operating expenses.  If the Company is unsuccessful in obtaining the necessary additional funding, it will most likely be forced to substantially reduce or cease operations.

The Company believes that it will need approximately $1,500,000 over the next 12 months for continued production manufacturing, research, development, and marketing activities, as well as for general corporate purposes.  

During 2013, the Company raised a total of $1,413,250 through the sale of 33,284,269 shares of common stock at prices ranging from $0.03 to $0.06 per share, which funds have been used to keep the Company current in its public reporting obligations and to pay certain other corporate obligations including the costs of development for its hospital disinfection system.  During the three months ended March 31, 2014, the Company raised a total of $1,049,250 through the sale of 16,050,000 shares of common stock at prices ranging from $0.05 to $0.085 per share.  The Company believes it will be able to raise additional funds from some of the same investors who have purchased shares from 2009 to 2014, although there is no assurance that these investors will purchase additional shares.  

The ability of the Company to continue as a going concern is dependent on its ability to successfully accomplish the plan described in the preceding paragraphs and eventually attain profitable operations.  The consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty.

NOTE 5     COMMITMENTS AND CONTINGENCIES

The Company is subject to certain claims and lawsuits arising in the normal course of business. In the opinion of management, uninsured losses, if any, resulting from the ultimate resolution of these matters will not have a material effect on the Company’s consolidated financial position, results of operations, or cash flows.

Litigation

Rakas vs. Medizone International, Inc. - A former consultant brought this action against the Company claiming the Company had failed to pay consulting fees under a consulting agreement.  In September 2001, the parties agreed to settle the matter for $25,000.  The Company, however, did not have the funds to pay the settlement and the plaintiff moved the court to enter a default judgment in the amount of $143,000 in January 2002.  On May 8, 2002, the court vacated the default judgment and requested that the Company post a bond of $25,000 to cover the settlement previously entered into by the parties.  The Company has been unable to post the required bond amount as of the date of this report.  Therefore, the Company has recorded, as part of accounts payable, the original default judgment in the amount of $143,000, plus fees totaling $21,308, as of March 31, 2014 and December 31, 2013.  The Company intends to contest the judgment if and when it is able to in the future.

Other Payables

As of March 31, 2014 and December 31, 2013, the Company has $224,852 of past due payables for which the Company has not received invoices or demands for over 10 years.  Although management of the Company does not believe that the amounts will be required to be paid, the amounts are recorded as other payables until such time as the Company is certain that no liability exists and until the statute of limitations has expired.

Operating Leases

The Company operates a certified laboratory located at Innovation Park, Queen’s University in Kingston, Ontario, Canada, which provides a primary research and development platform.  The lease term is month–to-month with a monthly lease payment of $1,375 Canadian dollars (“CD”) plus the applicable goods and services tax (“GST”).  Leases for a second laboratory space for full scale room testing and a storage unit are on a month-to-month basis with a monthly lease payment of CD$1,375 and CD$475, respectively, plus the applicable GST.  

The Company has a corporate office lease arrangement with monthly payments of $2,300 through December 31, 2014.

8

MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

NOTE 6     COMMON STOCK OPTIONS

On August 26, 2009, the Company granted options for the purchase of 1,500,000 shares of common stock to an outside consultant for services rendered, with an exercise price of $0.10 per share, exercisable for up to five years, but including vesting provisions as follows: (i) 500,000 of the options vested immediately on the date of grant, (ii) 500,000 options vested in September 2012, the date certified by the Company as the date the Company’s hospital disinfection program completes its beta-testing, and (iii) the remaining 500,000 options will vest on the date certified by the Company as the date that the Company’s process has been commercialized and a minimum of 50 units or devices have been sold to third parties by the Company.  As of March 31, 2014, 500,000 shares had not yet vested and represent a deferred expense of $48,698.

In May 2012, the Company granted options for the purchase of 1,000,000 shares of common stock to an individual for services.  Options for 550,000 shares have vested and the remaining options will vest on the date certified by the Company as the date that the other milestones are achieved.  The options have an exercise price of $0.17 per share, and are exercisable for up to five years.  The value of these options at the date of grant was $153,997, in connection with which the Company recognized $0 and $15,400 during the three months ended March 31, 2014 and 2013, respectively. The Company will recognize the remaining expense, totaling $69,300, when the achievement of the required milestones becomes probable.

In May 2012, the Company granted options for the purchase of 1,000,000 shares of common stock to an individual for medical consulting support services already performed.  Of these shares under option, 500,000 shares vested immediately on the grant date and 500,000 shares vested upon completion of certain milestones as of September 30, 2013.  The options have an exercise price of $0.17 per share and are exercisable for up to five years.  The grant date fair value of these options was $149,460, $25,409 of which the Company recognized during the three months ended March 31, 2013.  

In August 2013, the Company granted options for the purchase of 250,000 shares of common stock to a consultant.  These options are exercisable at $0.10 per share for five years from the date of grant.  Of these shares under option, 50,000 shares vested immediately and the remaining 200,000 shares will vest upon the achievement of certain milestones.  The value of these options on the date of grant was $22,075, of which the Company recognized $4,416 during the three months ended September 30, 2013.  As of March 31, 2014, 200,000 shares had not yet vested and represent deferred expense of $17,659 to be recognized when the achievement of the required milestones becomes probable.

In August 2013, the Company granted options for the purchase of 100,000 shares of common stock to an employee for services performed.  The options vested upon grant, have an exercise price of $0.10 per share, and are exercisable for up to five years.  The value of the options at the date of grant was $8,829, which the Company recognized as an expense during the three months ended September 30, 2013.

On February 26, 2014, the Company granted to a new director options for the purchase of 2,000,000 shares of common stock, with an exercise price of $0.1095 per share.  Of these options, 1,000,000 will vest on February 26, 2015 and the remaining 1,000,000 options will vest upon the successful achievement of certain milestones.  Unvested options would vest immediately in the event of a change in control of the Company.  The options are exercisable for five years. The grant date fair value of the options was $192,184.  The Company recognized $8,007 of expense in the first quarter of 2014, with $88,085 to be recognized over the remaining vesting period in connection with those options that vest on February 26, 2015.  Also, the Company will recognize an expense totaling $96,092 when the achievement of the required milestones becomes probable.

On February 26, 2014, the Company granted options to six consultants and service providers for the purchase of a total of 250,000 shares of common stock at an exercise price of $0.1095 per share.  Of these options, 200,000 vested immediately upon grant and the remaining 50,000 options will vest on January 9, 2015.  The options are exercisable for five years. The grant date fair value of these options was $24,023.  The Company recognized expense of $20,420 during the first quarter of 2014 and the remaining expense of $3,603 will be recognized over the remaining vesting period in connection with those options that vest on January 9, 2015.

The Company estimated the fair value of the stock options described in the above paragraphs at the date of the grant, based on the following weighted average assumptions:

Risk-free interest rate		1.50	%
Expected life	5 years
Expected volatility		136.44	%
Dividend yield		0.00	%

9

MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

NOTE 6     COMMON STOCK OPTIONS (continued)

A summary of the status of the Company’s outstanding options as of March 31, 2014 and for the three months then ended, is presented below:

	Shares		Weighted Average Exercise Price
Outstanding, beginning of the period		15,150,000	$	0.19
Granted		2,250,000	$	0.105
Expired/Canceled		-		-
Exercised		-		-
Outstanding, end of the period		17,400,000	$	0.18
Exercisable		14,200,000	$	0.19

The Company estimates the fair value of each stock option award by using the Black-Scholes option-pricing model, which model requires the use of exercise behavior data and the use of a number of assumptions including volatility of the Company’s stock price, the weighted average risk-free interest rate, and the weighted average expected life of the options. Because the Company does not pay dividends, the dividend rate variable in the Black-Scholes option-pricing model is zero. Expense of $28,427 and $40,809 related to stock options was recorded for the three-month periods ended March 31, 2014 and 2013, respectively.  As of March 31, 2014, the Company had various unvested outstanding options with related unrecognized expense of $323,437.  The Company will recognize this expense as these options vest over their remaining useful lives, which range from 8 to 58 months.

NOTE 7     STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS

During January, February and March 2014, the Company sold an aggregate of 9,000,000 restricted shares of common stock to six accredited investors for cash proceeds totaling $450,000, or $0.05 per share.

During March 2014, the Company sold an aggregate of 7,050,000 restricted shares of common stock to 16 accredited investors for cash proceeds totaling $599,250, or $0.085 per share.

During January, February, and March 2013, the Company sold an aggregate of 12,233,332 restricted shares of common stock to 12 accredited investors for cash proceeds totaling $367,000, or $0.03 per share.

Stock Purchase Agreement

On November 17, 2010, the Company entered into a Common Stock Purchase Agreement (the “Stock Purchase Agreement”), with Mammoth Corporation (“Mammoth”), which provided for a financing arrangement that was sometimes referred to as a committed equity line financing facility (or “Equity Line”). The Stock Purchase Agreement provided that, upon the terms and subject to the conditions in the Stock Purchase Agreement, Mammoth was committed to purchase up to $10,000,000 of shares of common stock over the 24-month term of the Stock Purchase Agreement.  Furthermore, in no event could Mammoth purchase any shares of the Company’s common stock which, when aggregated with all other shares of common stock then beneficially owned by Mammoth, would result in the beneficial ownership by Mammoth of more than 4.9% of the then outstanding shares of the Company’s common stock. These maximum share and beneficial ownership limitations could not be waived by the parties.

Under the terms of the Stock Purchase Agreement, the Company had the opportunity for a 24-month period, commencing on the date on which the Securities and Exchange Commission (“SEC”) first declared effective the registration statement filed in connection with the resale of shares issued under the Equity Line, to require Mammoth to purchase up to $10,000,000 in shares of common stock. For each share of common stock purchased under the Stock Purchase Agreement, Mammoth will pay to the Company a purchase price equal to 75% of the lowest closing bid price during the five-consecutive trading day period (the “Draw Down Pricing Period”) which preceded the date a draw down notice (the “Draw Down Notice”) was delivered to Mammoth (the “Draw Down Date”) in a manner provided by the Stock Purchase Agreement.  Subject to the limitations outlined below, the Company would, at its sole discretion, issue a Draw Down Notice to Mammoth, and Mammoth would then be irrevocably bound to purchase such shares.

10

MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

NOTE 7     STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS (continued)

Further, if the Company issued a Draw Down Notice and failed to deliver the shares to Mammoth on the applicable settlement date, and such failure continued for 10 trading days, the Company agreed to pay Mammoth, in addition to all other remedies available to Mammoth under the Stock Purchase Agreement, an amount in cash equal to $100 for each $5,000 of the Draw Down Amount for the first 10 days such delivery was late, and $350 for each $5,000 of the Draw Down Amount for each trading day beyond 10 trading days that such delivery was late.

In connection with the Stock Purchase Agreement, the Company granted registration rights to Mammoth, and agreed to register the resale of shares issued to Mammoth in connection with Draw Downs made in connection with the Stock Purchase Agreement.  In January 2011, the Company filed a registration statement to cover the resale by Mammoth of up to 66,666,667 shares of common stock under the Stock Purchase Agreement.  The Company was not permitted to make Draw Downs under the Stock Purchase Agreement at any time there was not an effective registration statement registering the resale of shares of common stock by Mammoth.  On January 25, 2011, the registration statement became effective by order of the SEC.  The Company made two Draw Down requests under the Stock Purchase Agreement in 2012. The Stock Purchase Agreement terminated automatically by its terms on January 25, 2013, the 24-month anniversary of the effective date of the registration statement.

NOTE 8     ACCOUNTS PAYABLE – RELATED PARTIES

As of March 31, 2014 and December 31, 2013, the Company had outstanding $235,047 and $234,677, respectively, owed to certain consultants for services rendered in prior years. These consultants are stockholders of the Company and therefore have been classified as related parties.

NOTE 9     SUBSEQUENT EVENTS

The Company has evaluated events subsequent to the period ended March 31, 2014, and noted none that require accounting or disclosure in the accompanying financial statements.

11

Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations

Introduction

Medizone International, Inc. and subsidiaries (collectively, “Medizone,” the “Company,” “we,” “us,” or “our”) is a Nevada corporation engaged in conducting research into the use of ozone in the disinfection of surgical and other medical treatment facilities and in other applications.  Until 2012, we operated as a development stage company until we began to sell our patented ozone disinfection system, AsepticSure.  Our current work is in the field of hospital disinfection, not human therapies.  We cannot predict when or if we will generate sufficient cash flows from operating activities to fund continuing or planned operations.  If we fail to obtain additional funding, we will be forced to suspend or permanently cease operations, and may need to seek protection under U.S. bankruptcy laws.

Recent Developments

In January 2014, the United States Patent and Trademark Office issued us U.S. Patent Number 8,636,951 titled “Bio-Terrorism Counteraction Using Ozone and Hydrogen Peroxide.”  We believe we now have significant intellectual property protection in place for both the health care related applications of our technology, and the government variant of AsepticSure to be used for building remediation following a biological attack.  We believe this protection positions us strongly for market entry into the United States.

Results of Operations

Quarters Ended March 31, 2014 and 2013

During the quarter ended March 31, 2014, we focused on raising capital which generated cash of $1,049,250 through the sale of 16,050,000 shares of common stock to accredited investors.  This capital will facilitate the next round of product manufacturing, expand our current distribution channels and be used for other operating expenses.  Also, we continued our approval from the U.S. Environmental Protection Agency (“EPA”) as well as development of a computer control system for the AsepticSure system.

For the quarter ended March 31, 2014, we had no revenues or associated cost of goods sold compared to revenues of $4,554 with cost of goods sold of $4,000 for the quarter ended March 31, 2013.

For the quarter ended March 31, 2014, we had a net loss of $394,883, compared with a net loss for the quarter ended March 31, 2013 of $387,298.  Our primary expenses are payroll and consulting fees, research and development costs, office expenses and interest expense.

For the quarters ended March 31, 2014 and 2013, we incurred $289,531 and $285,211, respectively, in general and administrative expenses. The majority of these expenses comprise payroll and consulting fees and professional fees.  The increase for the quarter ended March 31, 2014 over the prior year comparable period was primarily due to additional professional expenses.

For the quarters ended March 31, 2014 and 2013, we incurred $87,071 and $85,771, respectively, in research and development expenses.  Research and development expenses include consultant fees, interface development costs, prototypes, and research stage ozone generator and instrument development, and remained consistent with the prior year period.

Principal amounts owed on notes payable totaled $301,700 and $295,496 as of March 31, 2014 and December 31, 2013, respectively.  Interest expense on these obligations for the quarters ended March 31, 2014 and 2013 was $6,376 and $6,366, respectively. The applicable interest rates on this debt ranged from 4.63% to 10.00% per annum.

Liquidity and Capital Resources

As of March 31, 2014, our working capital deficiency was $2,648,898, compared to a working capital deficiency of $3,333,251 as of December 31, 2013. We have incurred significant losses from inception through March 31, 2014, which have resulted in an accumulated deficit of $31,816,867.  The stockholders’ deficit as of March 31, 2014 was $2,424,492, compared to $3,107,800 as of December 31, 2013.  This change is due to the sale of restricted shares of common stock being greater than the net loss for the quarter ended March 31, 2014.

We will continue to require additional financing to fund operations and to undertake our new business plans to further the ongoing testing, and to market our hospital and medical disinfection system.  We believe we will need approximately $1,500,000 over the next 12 months for continued production manufacturing, research, development, and marketing activities, as well as for general corporate purposes.  

12

During the quarter ended March 31, 2014, we generated cash of $1,049,250 through the sale of 16,050,000 shares of common stock to 19 accredited investors at prices ranging from $0.05 per share to $0.085 per share.  We anticipate that we will be able to raise additional funds, as needed, from certain of the accredited investors who have purchased shares during previous years, although we have no agreements at this time with any of these investors to purchase our securities, and there is no assurance that these investors will purchase additional shares.

Going Concern

Our unaudited condensed consolidated financial statements included in this report have been prepared on the assumption that the Company will continue as a going concern. There is substantial doubt that the Company will be able to continue as a going concern.  Through the date of this report, it has been necessary to rely upon financing from the sale of our equity securities to sustain operations as indicated above. Additional financing will be required if we are to continue as a going concern. If additional financing is not obtained in the near future, we will be required to curtail or discontinue operations, or seek protection under the bankruptcy laws. Even if additional financing becomes available, there can be no assurance that it will be on terms favorable to the Company. In any event, this additional financing will likely result in immediate and possibly substantial dilution to existing shareholders.

Forward-Looking Statements and Risks Affecting the Company

The statements contained in this report on Form 10-Q that are not historical are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements discuss our expectations, hopes, beliefs, anticipations, commitments, intentions and strategies regarding the future. They may be identified by the use of the words or phrases “believes,” “expects,” “anticipates,” “should,” “plans,” “estimates,” and “potential,” among others. Forward-looking statements include, but are not limited to, statements contained in Management's Discussion and Analysis of Financial Condition and Results of Operations regarding our financial performance, revenue and expense levels in the future and the sufficiency of existing assets to fund future operations and capital spending needs. Actual results could differ materially from the anticipated results or other expectations expressed in such forward-looking statements for the reasons detailed in our Annual Report on Form 10-K for the year ended December 31, 2013.

We believe that many of the risks previously discussed in our SEC filings are part of doing business in the industry in which we operate and will likely be present in all periods reported. The fact that certain risks are endemic to the industry does not lessen their significance. The forward-looking statements contained in this report are made as of the date of this report and we assume no obligation to update them or to update the reasons why actual results could differ from those projected in such forward-looking statements. Among others, risks and uncertainties that may affect our business, financial condition, performance, development, and results of operations include:

·   Rigorous government scrutiny and regulation of our products and planned products;

·   Potential effects of adverse publicity regarding ozone and related technologies or industries;

·   Failure to sustain or manage growth including the failure to continue to develop new products; and

·   The ability to obtain needed financing or to obtain funding on terms favorable to the Company.

Critical Accounting Policies and Estimates

This Management’s Discussion and Analysis of Financial Condition and Results of Operations is based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with US generally accepted accounting principles (“US GAAP”). The preparation of such statements requires our management to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. By their nature, these judgments are subject to an inherent degree of uncertainty. On an on-going basis, we evaluate these estimates, including those related to intangible assets, expenses, and income taxes. We base our estimates on historical experience and other facts and circumstances that are believed to be reasonable, and the results form the basis for making judgments about the carrying values of assets and liabilities. The actual results may differ from these estimates under different assumptions or conditions.

We commenced sales and emerged from the development stage in 2012.  We recognize revenue when a contractual arrangement exists, product is shipped, payment from the customer is reasonably assured, and the price is fixed or determinable.  We record customer deposits that have not yet been earned as unearned revenue. Revenue is recognized only when title and risk of loss passes to customers.

13

Our inventory consists of our AsepticSure product and is valued on a “specific identification basis.”  We purchase our inventory as a finished product from unrelated manufacturing companies. We write off 100% of the cost of inventory that we specifically identify and consider obsolete or excessive to fulfill future sales estimates. No inventory was obsolete or excessive as of March 31, 2014.

We account for equity securities issued for services rendered at the fair value of the securities on the date of grant.

Item 3.  Quantitative and Qualitative Disclosures About Market Risk

None.

Item 4.  Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as that term is defined in Rule 13a-15(e) and Rule 15d-15(e), promulgated by the SEC pursuant to the Securities Exchange Act of 1934. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in the Company’s reports filed under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer to allow timely decisions regarding required disclosure.

As of the end of the period covered by this quarterly report, our management, with the participation of our principal executive officer and principal financial officer, evaluated the Company’s disclosure controls and procedures. Based on this evaluation, our principal executive officer and principal financial officer concluded that as of the end of the period covered by this quarterly report, our disclosure controls and procedures were effective.

Changes in Internal Controls

We maintain a system of internal control over financial reporting that is designed to provide reasonable assurance that our books and records accurately reflect our transactions and that our established policies and procedures are followed. There were no changes to our internal control over financial reporting during the quarter ended March 31, 2014 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

14

PART II — OTHER INFORMATION

Item 1.  Legal Proceedings

There were no material developments during the quarter ended March 31, 2014 relative to the legal matters previously disclosed by the Company.

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds

During the quarter ended March 31, 2014, we sold an aggregate of 16,050,000 restricted shares of common stock to 19 accredited investors for cash proceeds totaling $1,049,250, ranging from $0.05 to $0.085 per share, as follows:

On January 31, 2014, we sold 1,000,000 shares of common stock to two accredited investors for $50,000, or $0.05 per share.

In February and March 2014, we sold 7,000,000 shares of common stock to three accredited investors for $350,000, or $0.05 per share.

On February 26, 2014, we sold 1,000,000 shares of common stock to an accredited investor who subsequently became a director of the Company for $50,000, or $0.05 per share.

On various dates in March 2014, we sold a total of 6,610,000 shares of common stock to 15 accredited investors for $561,850, or $0.085 per share.

On March 21, 2014, we sold 440,000 shares of common stock to a director of the Company for $37,400, or $0.085 per share.

The purchasers of the shares in these private placements included a director of the Company as well as existing stockholders not otherwise affiliated with the Company.  There were no underwriters or public solicitation involved in the offer or sale of these securities. The proceeds are being used for general operating expenses and the continuing development of the AsepticSure™ hospital disinfection system. The offer and sale of these securities was made without registration under the Securities Act of 1933, in reliance upon exemptions from registration, including, without limitation, the exemption provided under Section 4(a)(2) of the Securities Act for private and limited offers and sales of securities made solely to accredited investors.

Item 3.  Defaults Upon Senior Securities.

None.

Item 4.  Mine Safety Disclosures

Not applicable.

Item 5.  Other Information

In February 2014, the Board of Directors voted to enlarge the board of directors of the Company and appointed David Esposito, age 45, to serve as an independent director in the newly created position.  Mr. Esposito is the Managing Partner of Harvest Time Partners, Inc., which develops and provides resources to support and encourage individuals, families, and organizations to reach their full potential in an increasingly complex and uncertain world.  From 2011 to 2013, Mr. Esposito was Vice President, Commercial Operations, at Thermo Fisher Scientific.  Before joining Thermo Fisher Scientific, he was President and General Manager of Phadia US Inc., a specialty diagnostics company from 2009 until its acquisition by Thermo Fisher Scientific in 2011.  He was employed in various positions by Merck & Co., Inc. from 1996 to 2009, including stints as Executive Director of the Respiratory Marketing Team (2006-2007), New Commercial Model (2007-2008), and US Commercial Strategy (2008 – 2009).  He was a combat infantry officer (Lt., US Army Infantry, 101st Airborne Division) from 1990-1993 and served in Operation Desert Storm in 1991, where he was awarded the Bronze Star Medal for combat action in Iraq. He received a BS degree in civil engineering at the United States Military Academy (West Point), and an MBA from Syracuse University.  He also completed an executive education program, Competitive Marketing Strategy Program, at The Wharton School (University of Pennsylvania).

15

The Board granted stock options to Mr. Esposito at the time of his appointment as follows:  (1) an option to purchase 1,000,000 shares of common stock, which vests one year from the date of grant (February 26, 2015); and (2) an option to purchase 1,000,000 shares of common stock which vests as certain milestones are met by the Company in the commercialization of the AsepticSure® system.  Unvested options would vest immediately in the event of a change in control of the Company.  All options are exercisable at a price of $0.1095 per share, the price of the Company’s common stock at the close of business on the date of grant (February 26, 2014).

On February 26, 2014, Mr. Esposito purchased 1,000,000 shares of common stock for cash of $50,000, or $0.05 per share.  Also, on March 21, 2014, he purchased an additional 440,000 shares of common stock for cash of $37,400, or $0.085 per share.

We filed a Current Report on Form 8-K on February 28, 2014 to report the election of our new director and the other matters discussed in this Item 5.

Item 6.  Exhibits

Exhibit 31.1	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Exhibit 31.2	Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Exhibit 32.1	Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Exhibit 32.2	Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document**
101.SCH	XBRL Taxonomy Extension Schema**
101.CAL	XBRL Taxonomy Extension Calculation Linkbase**
101.DEF	XBRL Taxonomy Extension Definition Linkbase**
101.LAB	XBRL Taxonomy Extension Label Linkbase**
101.PRE	XBRL Taxonomy Extension Presentation Linkbase**

** Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934 (“Exchange Act”) and otherwise are not subject to liability.

16

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MEDIZONE INTERNATIONAL, INC.

(Registrant)

/s/ Edwin G. Marshall                                       

Edwin G. Marshall, Chairman and Chief Executive

Officer (Principal Executive Officer)

/s/ Thomas (Tommy) E. Auger                        

Thomas (Tommy) E. Auger, Chief Financial Officer

(Principal Financial and Accounting Officer)

April 28, 2014

17

EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO RULE 13a-14

UNDER THE SECURITIES EXCHANGE ACT OF 1934

I, Edwin G. Marshall, certify that:

(1)           I have reviewed this quarterly report on Form 10-Q of Medizone International, Inc. for the quarter ended March 31, 2014;

(2)           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3)           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4)           The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

(a)           Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)           Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

(d)           Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

(5)           The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions);

(a)           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information;

(b)           Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 28, 2014

 /s/ Edwin G. Marshall                                                     

Edwin G. Marshall

Chief Executive Officer (Principal Executive Officer)

EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO RULE 13a-14

UNDER THE SECURITIES EXCHANGE ACT OF 1934

I, Tommy E. Auger, certify that:

(1)           I have reviewed this quarterly report on Form 10-Q of Medizone International, Inc. for the quarter ended March 31, 2014;

(2)           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3)           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4)           The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

(a)           Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)           Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

(d)           Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

(5)           The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions);

(a)           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information;

(b)           Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 28, 2014

/s/ Tommy E. Auger                                                           

Tommy E. Auger

Chief Financial Officer (Principal Financial and Accounting Officer)

EX-32.1

Exhibit 32.1

Certification Pursuant to Section 1350 of Chapter 63

of Title 18 of the United States Code

I, Edwin G. Marshall, the Chief Executive Officer of Medizone International, Inc. (“Medizone”), certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(i)           the accompanying Form 10-Q of Medizone for the quarter ended March 31, 2014 (the “Form 10-Q”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii)           the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Medizone.

/s/ Edwin G. Marshall                                                  

Edwin G. Marshall

Chief Executive Officer (Principal Executive Officer)

April 28, 2014

EX-32.2

Exhibit 32.2

Certification Pursuant to Section 1350 of Chapter 63

of Title 18 of the United States Code

I, Tommy E. Auger, the Chief Financial Officer of Medizone International, Inc. (“Medizone”), certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(i)           the accompanying Form 10-Q of Medizone for the quarter ended March 31, 2014 (the “Form 10-Q”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii)           the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Medizone.

/s/ Tommy E. Auger                                                       

Tommy E. Auger

Chief Financial Officer

(Principal Financial and Accounting Officer)

April 28, 2014

XML

NOTE 8 ACCOUNTS PAYABLE - RELATED PARTIES (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Related Party Transactions [Abstract]
Accounts Payable, Related Parties, Current	$ 235,047	$ 234,677

XML

NOTE 4 GOING CONCERN

3 Months Ended

Mar. 31, 2014

Going Concern Disclosure [Abstract]

Going Concern Disclosure [Text Block]

NOTE 4     GOING CONCERN

The Company’s consolidated financial statements are prepared using US GAAP applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business.  The Company has incurred significant losses from its inception through March 31, 2014, which have resulted in an accumulated deficit of $31,816,867 as of March 31, 2014.  The Company does not have funds sufficient to cover its operating costs for the next 12 months, has a working capital deficit of $2,648,898, and has relied exclusively on debt and equity financing.  Accordingly, there is substantial doubt about its ability to continue as a going concern.

Continuation of the Company as a going concern is dependent upon future revenues, obtaining additional capital and ultimately, upon the Company’s attaining profitable operations.  The Company will require substantial additional funds to complete the continued development of its products, product manufacturing, and to fund expected additional losses, until revenues are sufficient to cover the Company’s operating expenses.  If the Company is unsuccessful in obtaining the necessary additional funding, it will most likely be forced to substantially reduce or cease operations.

The Company believes that it will need approximately $1,500,000 over the next 12 months for continued production manufacturing, research, development, and marketing activities, as well as for general corporate purposes.  

During 2013, the Company raised a total of $1,413,250 through the sale of 33,284,269 shares of common stock at prices ranging from $0.03 to $0.06 per share, which funds have been used to keep the Company current in its public reporting obligations and to pay certain other corporate obligations including the costs of development for its hospital disinfection system.  During the three months ended March 31, 2014, the Company raised a total of $1,049,250 through the sale of 16,050,000 shares of common stock at prices ranging from $0.05 to $0.085 per share.  The Company believes it will be able to raise additional funds from some of the same investors who have purchased shares from 2009 to 2014, although there is no assurance that these investors will purchase additional shares.  

The ability of the Company to continue as a going concern is dependent on its ability to successfully accomplish the plan described in the preceding paragraphs and eventually attain profitable operations.  The consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty.

XML

NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE

3 Months Ended

Mar. 31, 2014

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

NOTE 3     BASIC AND DILUTED NET LOSS PER COMMON SHARE

The computations of basic and diluted net loss per common share are based on the weighted average number of common shares outstanding during the periods as follows:

	For the Three Months Ended March 31,
	2014			2013
Numerator: Net loss	$	(394,883	)	$	(387,298	)
Denominator: Weighted average number of common shares outstanding		324,076,274			295,469,004
Basic and diluted net loss per common share	$	(0.00	)	$	(0.00	)

Common stock equivalents, consisting of options, have not been included in the calculation as their effect is antidilutive for the periods presented.

XML

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current Assets:
Cash	$ 744,426	$ 81,856
Inventory	265,234	265,234
Prepaid expenses	46,092	33,085
Total Current Assets	1,055,752	380,175
Property and equipment, net	1,353	1,616
Other Assets:
Trademark and patents, net	218,781	219,563
Lease deposit	4,272	4,272
Total Other Assets	223,053	223,835
Total Assets	1,280,158	605,626
Current Liabilities:
Accounts payable	458,299	477,563
Accounts payable – related parties	235,047	234,677
Accrued expenses	526,093	522,179
Accrued expenses – related parties	1,928,659	1,928,659
Customer deposits	30,000	30,000
Other payables	224,852	224,852
Notes payable	301,700	295,496
Total Current Liabilities	3,704,650	3,713,426
Commitments and Contingencies (Note 5)
Stockholders’ Deficit:
Preferred stock, $0.00001 par value: 50,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.001 par value; 395,000,000 shares authorized; 338,105,496 and 322,055,496 shares outstanding, respectively	338,106	322,055
Additional paid-in capital	29,080,024	28,018,398
Accumulated other comprehensive loss	(25,755)	(26,269)
Accumulated deficit	(31,816,867)	(31,421,984)
Total Stockholders' Deficit	(2,424,492)	(3,107,800)
Total Liabilities and Stockholders’ Deficit	$ 1,280,158	$ 605,626

XML

NOTE 1 BASIS OF PRESENTATION

3 Months Ended

Mar. 31, 2014

Disclosure Text Block [Abstract]

Business Description and Basis of Presentation [Text Block]

NOTE 1     BASIS OF PRESENTATION

The financial information included herein is unaudited and has been prepared consistent with US generally accepted accounting principles (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all information and notes required by US GAAP for complete financial statements. These notes should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2013. In the opinion of management, these financial statements contain all adjustments (consisting solely of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended March 31, 2014 are not necessarily indicative of the results to be expected for the full year.

XML

NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Fair Value Assumptions of Stock Options	3 Months Ended
	Mar. 31, 2014
Schedule of Fair Value Assumptions of Stock Options [Abstract]
Risk-free interest rate	1.50%
Expected life	5 years
Expected volatility	136.44%
Dividend yield	0.00%

XML

NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS (Details) (USD $)	3 Months Ended		12 Months Ended			3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2012 Stock Purchase Agreement [Member]	Dec. 31, 2010 Stock Purchase Agreement [Member]	Dec. 31, 2010 Stock Purchase Agreement [Member] Maximum [Member]	Mar. 31, 2014 Restricted Stock Issued During January, February and March 2014 [Member]	Mar. 31, 2014 Restricted Stock Issued During March 2014 [Member]	Mar. 31, 2013 Restricted Stock Issued During January, February and March 2013 [Member]
NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS (Details) [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross						9,000,000	7,050,000	12,233,332
Number of Investors						6	16	12
Proceeds from Issuance or Sale of Equity	$ 1,049,250	$ 367,000				$ 450,000	$ 599,250	$ 367,000
Shares Issued, Price Per Share						$ 0.05	$ 0.085	$ 0.03
Stock Purchase Agreement, Draw Down Notice, Description				On November 17, 2010, the Company entered into a Common Stock Purchase Agreement (the "Stock Purchase Agreement"), with Mammoth Corporation ("Mammoth"), which provided for a financing arrangement that was sometimes referred to as a committed equity line financing facility (or "Equity Line"). The Stock Purchase Agreement provided that, upon the terms and subject to the conditions in the Stock Purchase Agreement, Mammoth was committed to purchase up to $10,000,000 of shares of common stock over the 24-month term of the Stock Purchase Agreement. Furthermore, in no event could Mammoth purchase any shares of the Company's common stock which, when aggregated with all other shares of common stock then beneficially owned by Mammoth, would result in the beneficial ownership by Mammoth of more than 4.9% of the then outstanding shares of the Company's common stock. These maximum share and beneficial ownership limitations could not be waived by the parties.Under the terms of the Stock Purchase Agreement, the Company had the opportunity for a 24-month period, commencing on the date on which the Securities and Exchange Commission ("SEC") first declared effective the registration statement filed in connection with the resale of shares issued under the Equity Line, to require Mammoth to purchase up to $10,000,000 in shares of common stock.
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable				10,000,000
Stock Purchase Agreement, Term of Agreement				24 months
Equity Method Investment, Ownership Percentage					4.90%
Stock purchase agreement, price description				75% of the lowest closing bid price during the five-consecutive trading day period (the "Draw Down Pricing Period") which preceded the date a draw down notice (the "Draw Down Notice") was delivered to Mammoth (the "Draw Down Date") in a manner provided by the Stock Purchase Agreement
Stock Purchase Agreement, Draw Down Notice, Events of Default				Further, if the Company issued a Draw Down Notice and failed to deliver the shares to Mammoth on the applicable settlement date, and such failure continued for 10 trading days, the Company agreed to pay Mammoth, in addition to all other remedies available to Mammoth under the Stock Purchase Agreement, an amount in cash equal to $100 for each $5,000 of the Draw Down Amount for the first 10 days such delivery was late, and $350 for each $5,000 of the Draw Down Amount for each trading day beyond 10 trading days that such delivery was late.
Stock Purchase Agreement, Maximum Number of Shares to be Resold				$ 66,666,667
Stock Purchase Agreement, Draw Down Notice Requests			2

XML

NOTE 2 CANADIAN FOUNDATION FOR GLOBAL HEALTH

3 Months Ended

Mar. 31, 2014

Disclosure Text Block [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

NOTE 2     CANADIAN FOUNDATION FOR GLOBAL HEALTH

In late 2008, the Company assisted in the formation of the Canadian Foundation for Global Health (“CFGH”), a not-for-profit foundation based in Ottawa, Canada. The Company helped establish CFGH for two primary purposes: (1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with the Company for research purposes that is best positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit; and (2) to provide a means for the Company to use a tiered pricing structure for services and products in emerging economies and extend the reach of the Company’s technology to as many in need as possible.

Accounting standards require a variable interest entity (“VIE”) to be consolidated by a company if that company absorbs a majority of the VIE’s expected losses and/or receives a majority of the entity’s expected residual returns as a result of holding variable interests, which are the ownership, contractual, or other financial interests in the entity. In addition, a legal entity may be considered to be a VIE, if it does not have sufficient equity at risk to finance its own activities without relying on financial support from other parties. If the legal entity is a VIE, then the reporting entity determined to be the primary beneficiary of the VIE must consolidate its financial statements with those of the VIE. The Company determined that CFGH met the requirements of a VIE effective upon the first advance to CFGH on February 12, 2009. Accordingly, the financial statements of CFGH have been consolidated with those of the Company for all periods presented.

XML

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, par value (in Dollars per share)	$ 0.00001	$ 0.00001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares authorized	395,000,000	395,000,000
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares outstanding	338,105,496	322,055,496

XML

NOTE 2 CANADIAN FOUNDATION FOR GLOBAL HEALTH (Details)	3 Months Ended
	Mar. 31, 2014
Disclosure Text Block [Abstract]
Variable Interest Entity, Qualitative or Quantitative Information, Purpose of VIE	(1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with the Company for research purposes that is best positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit; and (2) to provide a means for the Company to use a tiered pricing structure for services and products in emerging economies and extend the reach of the Company's technology to as many in need as possible.

XML

Document And Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 28, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	Medizone International Inc
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		338,105,496
Amendment Flag	false
Entity Central Index Key	0000753772
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Mar. 31, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q1

XML

NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE (Details) - Schedule of Earnings Per Share, Basic and Diluted (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Schedule of Earnings Per Share, Basic and Diluted [Abstract]
Numerator: Net loss	$ (394,883)	$ (387,298)
Denominator: Weighted average number of common shares outstanding	324,076,274	295,469,004
Basic and diluted net loss per common share	$ 0.00	$ 0.00

XML

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Revenues	$ 0	$ 4,554
Operating Expenses:
Cost of revenues	0	4,000
General and administrative	289,531	285,211
Research and development	87,071	85,771
Depreciation and amortization	11,905	10,504
Total Operating Expenses	388,507	385,486
Loss from Operations	(388,507)	(380,932)
Interest expense	(6,376)	(6,366)
Net Loss	(394,883)	(387,298)
Other comprehensive gain (loss) on foreign currency translation	514	(172)
Total Comprehensive Loss	$ (394,369)	$ (387,470)
Basic and Diluted Net Loss per Common Share (in Dollars per share)	$ 0.00	$ 0.00
Weighted Average Number of Common Shares Outstanding (in Shares)	324,076,274	295,469,004

XML

NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS

3 Months Ended

Mar. 31, 2014

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

NOTE 7     STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS

During January, February and March 2014, the Company sold an aggregate of 9,000,000 restricted shares of common stock to six accredited investors for cash proceeds totaling $450,000, or $0.05 per share.

During March 2014, the Company sold an aggregate of 7,050,000 restricted shares of common stock to 16 accredited investors for cash proceeds totaling $599,250, or $0.085 per share.

During January, February, and March 2013, the Company sold an aggregate of 12,233,332 restricted shares of common stock to 12 accredited investors for cash proceeds totaling $367,000, or $0.03 per share.

Stock Purchase Agreement

On November 17, 2010, the Company entered into a Common Stock Purchase Agreement (the “Stock Purchase Agreement”), with Mammoth Corporation (“Mammoth”), which provided for a financing arrangement that was sometimes referred to as a committed equity line financing facility (or “Equity Line”). The Stock Purchase Agreement provided that, upon the terms and subject to the conditions in the Stock Purchase Agreement, Mammoth was committed to purchase up to $10,000,000 of shares of common stock over the 24-month term of the Stock Purchase Agreement.  Furthermore, in no event could Mammoth purchase any shares of the Company’s common stock which, when aggregated with all other shares of common stock then beneficially owned by Mammoth, would result in the beneficial ownership by Mammoth of more than 4.9% of the then outstanding shares of the Company’s common stock. These maximum share and beneficial ownership limitations could not be waived by the parties.

Under the terms of the Stock Purchase Agreement, the Company had the opportunity for a 24-month period, commencing on the date on which the Securities and Exchange Commission (“SEC”) first declared effective the registration statement filed in connection with the resale of shares issued under the Equity Line, to require Mammoth to purchase up to $10,000,000 in shares of common stock. For each share of common stock purchased under the Stock Purchase Agreement, Mammoth will pay to the Company a purchase price equal to 75% of the lowest closing bid price during the five-consecutive trading day period (the “Draw Down Pricing Period”) which preceded the date a draw down notice (the “Draw Down Notice”) was delivered to Mammoth (the “Draw Down Date”) in a manner provided by the Stock Purchase Agreement.  Subject to the limitations outlined below, the Company would, at its sole discretion, issue a Draw Down Notice to Mammoth, and Mammoth would then be irrevocably bound to purchase such shares.

Further, if the Company issued a Draw Down Notice and failed to deliver the shares to Mammoth on the applicable settlement date, and such failure continued for 10 trading days, the Company agreed to pay Mammoth, in addition to all other remedies available to Mammoth under the Stock Purchase Agreement, an amount in cash equal to $100 for each $5,000 of the Draw Down Amount for the first 10 days such delivery was late, and $350 for each $5,000 of the Draw Down Amount for each trading day beyond 10 trading days that such delivery was late.

In connection with the Stock Purchase Agreement, the Company granted registration rights to Mammoth, and agreed to register the resale of shares issued to Mammoth in connection with Draw Downs made in connection with the Stock Purchase Agreement.  In January 2011, the Company filed a registration statement to cover the resale by Mammoth of up to 66,666,667 shares of common stock under the Stock Purchase Agreement.  The Company was not permitted to make Draw Downs under the Stock Purchase Agreement at any time there was not an effective registration statement registering the resale of shares of common stock by Mammoth.  On January 25, 2011, the registration statement became effective by order of the SEC.  The Company made two Draw Down requests under the Stock Purchase Agreement in 2012. The Stock Purchase Agreement terminated automatically by its terms on January 25, 2013, the 24-month anniversary of the effective date of the registration statement.

XML

NOTE 6 COMMON STOCK OPTIONS

3 Months Ended

Mar. 31, 2014

Disclosure Text Block Supplement [Abstract]

Shareholders' Equity and Share-based Payments [Text Block]

NOTE 6     COMMON STOCK OPTIONS

On August 26, 2009, the Company granted options for the purchase of 1,500,000 shares of common stock to an outside consultant for services rendered, with an exercise price of $0.10 per share, exercisable for up to five years, but including vesting provisions as follows: (i) 500,000 of the options vested immediately on the date of grant, (ii) 500,000 options vested in September 2012, the date certified by the Company as the date the Company’s hospital disinfection program completes its beta-testing, and (iii) the remaining 500,000 options will vest on the date certified by the Company as the date that the Company’s process has been commercialized and a minimum of 50 units or devices have been sold to third parties by the Company.  As of March 31, 2014, 500,000 shares had not yet vested and represent a deferred expense of $48,698.

In May 2012, the Company granted options for the purchase of 1,000,000 shares of common stock to an individual for services.  Options for 550,000 shares have vested and the remaining options will vest on the date certified by the Company as the date that the other milestones are achieved.  The options have an exercise price of $0.17 per share, and are exercisable for up to five years.  The value of these options at the date of grant was $153,997, in connection with which the Company recognized $0 and $15,400 during the three months ended March 31, 2014 and 2013, respectively. The Company will recognize the remaining expense, totaling $69,300, when the achievement of the required milestones becomes probable.

In May 2012, the Company granted options for the purchase of 1,000,000 shares of common stock to an individual for medical consulting support services already performed.  Of these shares under option, 500,000 shares vested immediately on the grant date and 500,000 shares vested upon completion of certain milestones as of September 30, 2013.  The options have an exercise price of $0.17 per share and are exercisable for up to five years.  The grant date fair value of these options was $149,460, $25,409 of which the Company recognized during the three months ended March 31, 2013.  

In August 2013, the Company granted options for the purchase of 250,000 shares of common stock to a consultant.  These options are exercisable at $0.10 per share for five years from the date of grant.  Of these shares under option, 50,000 shares vested immediately and the remaining 200,000 shares will vest upon the achievement of certain milestones.  The value of these options on the date of grant was $22,075, of which the Company recognized $4,416 during the three months ended September 30, 2013.  As of March 31, 2014, 200,000 shares had not yet vested and represent deferred expense of $17,659 to be recognized when the achievement of the required milestones becomes probable.

In August 2013, the Company granted options for the purchase of 100,000 shares of common stock to an employee for services performed.  The options vested upon grant, have an exercise price of $0.10 per share, and are exercisable for up to five years.  The value of the options at the date of grant was $8,829, which the Company recognized as an expense during the three months ended September 30, 2013.

On February 26, 2014, the Company granted to a new director options for the purchase of 2,000,000 shares of common stock, with an exercise price of $0.1095 per share.  Of these options, 1,000,000 will vest on February 26, 2015 and the remaining 1,000,000 options will vest upon the successful achievement of certain milestones.  Unvested options would vest immediately in the event of a change in control of the Company.  The options are exercisable for five years. The grant date fair value of the options was $192,184.  The Company recognized $8,007 of expense in the first quarter of 2014, with $88,085 to be recognized over the remaining vesting period in connection with those options that vest on February 26, 2015.  Also, the Company will recognize an expense totaling $96,092 when the achievement of the required milestones becomes probable.

On February 26, 2014, the Company granted options to six consultants and service providers for the purchase of a total of 250,000 shares of common stock at an exercise price of $0.1095 per share.  Of these options, 200,000 vested immediately upon grant and the remaining 50,000 options will vest on January 9, 2015.  The options are exercisable for five years. The grant date fair value of these options was $24,023.  The Company recognized expense of $20,420 during the first quarter of 2014 and the remaining expense of $3,603 will be recognized over the remaining vesting period in connection with those options that vest on January 9, 2015.

The Company estimated the fair value of the stock options described in the above paragraphs at the date of the grant, based on the following weighted average assumptions:

Risk-free interest rate		1.50	%
Expected life	5 years
Expected volatility		136.44	%
Dividend yield		0.00	%

A summary of the status of the Company’s outstanding options as of March 31, 2014 and for the three months then ended, is presented below:

	Shares		Weighted Average Exercise Price
Outstanding, beginning of the period		15,150,000	$	0.19
Granted		2,250,000	$	0.105
Expired/Canceled		-		-
Exercised		-		-
Outstanding, end of the period		17,400,000	$	0.18
Exercisable		14,200,000	$	0.19

The Company estimates the fair value of each stock option award by using the Black-Scholes option-pricing model, which model requires the use of exercise behavior data and the use of a number of assumptions including volatility of the Company’s stock price, the weighted average risk-free interest rate, and the weighted average expected life of the options. Because the Company does not pay dividends, the dividend rate variable in the Black-Scholes option-pricing model is zero. Expense of $28,427 and $40,809 related to stock options was recorded for the three-month periods ended March 31, 2014 and 2013, respectively.  As of March 31, 2014, the Company had various unvested outstanding options with related unrecognized expense of $323,437.  The Company will recognize this expense as these options vest over their remaining useful lives, which range from 8 to 58 months.

XML

NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Share-Based Compensation, Stock Options, Activity (USD $)	3 Months Ended
	Mar. 31, 2014
Shares [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Share-Based Compensation, Stock Options, Activity [Line Items]
Outstanding, beginning of the period	15,150,000
Granted	2,250,000
Expired/Canceled	0
Exercised	0
Outstanding, end of the period	17,400,000
Exercisable	14,200,000
Weighted Average Exercise Price [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Share-Based Compensation, Stock Options, Activity [Line Items]
Outstanding, beginning of the period	$ 0.19
Granted	$ 0.105
Expired/Canceled	$ 0
Exercised	$ 0
Outstanding, end of the period	$ 0.18
Exercisable	$ 0.19

XML

NOTE 4 GOING CONCERN (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
NOTE 4 GOING CONCERN (Details) [Line Items]
Retained Earnings (Accumulated Deficit)	$ (31,816,867)	$ (31,421,984)
Working Capital (Deficit)	(2,648,898)
Going Concern Note	The Company believes that it will need approximately $1,500,000 over the next 12 months for continued production manufacturing, research, development, and marketing activities, as well as for general corporate purposes.
Proceeds from Issuance of Common Stock	$ 1,049,250	$ 1,413,250
Stock Issued During Period, Shares, New Issues	16,050,000	33,284,269
Minimum [Member]
NOTE 4 GOING CONCERN (Details) [Line Items]
Sale of Stock, Price Per Share	$ 0.05	$ 0.03
Maximum [Member]
NOTE 4 GOING CONCERN (Details) [Line Items]
Sale of Stock, Price Per Share	$ 0.085	$ 0.06

XML

NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE (Tables)

3 Months Ended

Mar. 31, 2014

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

The computations of basic and diluted net loss per common share are based on the weighted average number of common shares outstanding during the periods as follows:

	For the Three Months Ended March 31,
	2014			2013
Numerator: Net loss	$	(394,883	)	$	(387,298	)
Denominator: Weighted average number of common shares outstanding		324,076,274			295,469,004
Basic and diluted net loss per common share	$	(0.00	)	$	(0.00	)

XML

NOTE 8 ACCOUNTS PAYABLE - RELATED PARTIES

3 Months Ended

Mar. 31, 2014

Related Party Transactions [Abstract]

Related Party Transactions Disclosure [Text Block]

NOTE 8     ACCOUNTS PAYABLE – RELATED PARTIES

As of March 31, 2014 and December 31, 2013, the Company had outstanding $235,047 and $234,677, respectively, owed to certain consultants for services rendered in prior years. These consultants are stockholders of the Company and therefore have been classified as related parties.

XML

NOTE 9 SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2014

Subsequent Events [Abstract]

Subsequent Events [Text Block]

NOTE 9     SUBSEQUENT EVENTS

The Company has evaluated events subsequent to the period ended March 31, 2014, and noted none that require accounting or disclosure in the accompanying financial statements.

XML

NOTE 6 COMMON STOCK OPTIONS (Tables)

3 Months Ended

Mar. 31, 2014

Disclosure Text Block Supplement [Abstract]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

The Company estimated the fair value of the stock options described in the above paragraphs at the date of the grant, based on the following weighted average assumptions:

Risk-free interest rate		1.50	%
Expected life	5 years
Expected volatility		136.44	%
Dividend yield		0.00	%

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of the status of the Company’s outstanding options as of March 31, 2014 and for the three months then ended, is presented below:

	Shares		Weighted Average Exercise Price
Outstanding, beginning of the period		15,150,000	$	0.19
Granted		2,250,000	$	0.105
Expired/Canceled		-		-
Exercised		-		-
Outstanding, end of the period		17,400,000	$	0.18
Exercisable		14,200,000	$	0.19

XML

NOTE 6 COMMON STOCK OPTIONS (Details) (USD $)	3 Months Ended							12 Months Ended	3 Months Ended		12 Months Ended			3 Months Ended	12 Months Ended		3 Months Ended	12 Months Ended		3 Months Ended	12 Months Ended			3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014 Employee Stock Option [Member]	Mar. 31, 2013 Employee Stock Option [Member]	Mar. 31, 2014 Employee Stock Option [Member] Minimum [Member]	Mar. 31, 2014 Employee Stock Option [Member] Maximum [Member]	Mar. 31, 2014 Stock Options Issued August 26, 2009 [Member]	Dec. 31, 2009 Stock Options Issued August 26, 2009 [Member]	Mar. 31, 2014 Options Issued for Services, May 2012 [Member]	Mar. 31, 2013 Options Issued for Services, May 2012 [Member]	Dec. 31, 2013 Options Issued for Services, May 2012 [Member]	Dec. 31, 2012 Options Issued for Services, May 2012 [Member]	Dec. 31, 2010 Options Issued for Services, May 2012 [Member]	Mar. 31, 2013 Options Granted for Medical Consulting Support Services, May 2012 [Member]	Dec. 31, 2013 Options Granted for Medical Consulting Support Services, May 2012 [Member]	Dec. 31, 2012 Options Granted for Medical Consulting Support Services, May 2012 [Member]	Sep. 30, 2013 Options Granted to a Consultant in August 2013 [Member]	Dec. 31, 2013 Options Granted to a Consultant in August 2013 [Member]	Mar. 31, 2014 Options Granted to a Consultant in August 2013 [Member]	Sep. 30, 2013 Options Granted to Employee for Services in August 2013 [Member]	Dec. 31, 2013 Options Granted to Employee for Services in August 2013 [Member]	Mar. 31, 2014 Options Granted to Directors, February 26, 2014 [Member] Options Vesting February 26, 2015 [Member]	Mar. 31, 2014 Options Granted to Directors, February 26, 2014 [Member] Options Vesting When Achievement of Required Milestones Becomes Probable [Member]	Mar. 31, 2014 Options Granted to Directors, February 26, 2014 [Member]	Mar. 31, 2014 Options Granted to Consultants, February 26, 2014 [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)								1,500,000					1,000,000			1,000,000		250,000			100,000			2,000,000	250,000
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share)								$ 0.10				$ 0.17				$ 0.17		$ 0.10			$ 0.10			$ 0.1095	$ 0.1095
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period								5 years				5 years				5 years		5 years			5 years			5 years	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights								(i) 500,000 of the options vested immediately on the date of grant, (ii) 500,000 options vested in September 2012, the date certified by the Company as the date the Company's hospital disinfection program completes its beta-testing, and (iii) the remaining 500,000 options will vest on the date certified by the Company as the date that the Company's process has been commercialized and a minimum of 50 units or devices have been sold to third parties by the Company.																1,000,000 will vest on February 26, 2015 and the remaining 1,000,000 options will vest upon the successful achievement of certain milestones	200,000 vested immediately upon grant and the remaining 50,000 options will vest on January 9, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares (in Shares)							500,000											200,000	200,000
Share-based Compensation	$ 28,427	$ 40,809	$ 28,427	$ 40,809			$ 48,698		$ 0	$ 15,400				$ 25,409			$ 4,416			$ 8,829				$ 8,007	$ 20,420
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in Shares)											550,000				500,000	500,000		50,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)												$ 153,997
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options			$ 323,437						$ 69,300										$ 17,659			$ 88,085	$ 96,092		$ 3,603
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)																$ 149,460		$ 22,075						$ 192,184	$ 24,023
Number of consultants and service providers issued options	6
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term					8 months	58 months

XML

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash Flows from Operating Activities:
Net loss	$ (394,883)	$ (387,298)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	11,905	10,483
Stock-based compensation	28,427	40,809
Changes in operating assets and liabilities:
Prepaid expenses	14,162	(15,579)
Customer deposits	0	(4,554)
Accounts payable and accounts payable – related parties	(18,894)	45,473
Accrued expenses and accrued expenses – related parties	3,914	6,501
Net Cash Used in Operating Activities	(355,369)	(304,165)
Cash Flows from Investing Activities:
Purchase of trademark and patents	(10,860)	(6,464)
Net Cash Used in Investing Activities	(10,860)	(6,464)
Cash Flows from Financing Activities:
Principal payments on notes payable	(20,965)	(18,722)
Issuance of common stock for cash	1,049,250	367,000
Net Cash Provided by Financing Activities	1,028,285	348,278
Effect of Foreign Currency Exchange Rates	514	(172)
Net increase in cash	662,570	37,477
Cash as of beginning of the period	81,856	12,456
Cash as of end of the period	744,426	49,933
Cash paid for interest	462	307
NON-CASH FINANCING ACTIVITIES:
Financing of insurance policies	$ 27,169	$ 27,250

XML

NOTE 5 COMMITMENTS AND CONTINGENCIES

3 Months Ended

Mar. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

NOTE 5     COMMITMENTS AND CONTINGENCIES

The Company is subject to certain claims and lawsuits arising in the normal course of business. In the opinion of management, uninsured losses, if any, resulting from the ultimate resolution of these matters will not have a material effect on the Company’s consolidated financial position, results of operations, or cash flows.

Litigation

Rakas vs. Medizone International, Inc. - A former consultant brought this action against the Company claiming the Company had failed to pay consulting fees under a consulting agreement.  In September 2001, the parties agreed to settle the matter for $25,000.  The Company, however, did not have the funds to pay the settlement and the plaintiff moved the court to enter a default judgment in the amount of $143,000 in January 2002.  On May 8, 2002, the court vacated the default judgment and requested that the Company post a bond of $25,000 to cover the settlement previously entered into by the parties.  The Company has been unable to post the required bond amount as of the date of this report.  Therefore, the Company has recorded, as part of accounts payable, the original default judgment in the amount of $143,000, plus fees totaling $21,308, as of March 31, 2014 and December 31, 2013.  The Company intends to contest the judgment if and when it is able to in the future.

Other Payables

As of March 31, 2014 and December 31, 2013, the Company has $224,852 of past due payables for which the Company has not received invoices or demands for over 10 years.  Although management of the Company does not believe that the amounts will be required to be paid, the amounts are recorded as other payables until such time as the Company is certain that no liability exists and until the statute of limitations has expired.

Operating Leases

The Company operates a certified laboratory located at Innovation Park, Queen’s University in Kingston, Ontario, Canada, which provides a primary research and development platform.  The lease term is month–to-month with a monthly lease payment of $1,375 Canadian dollars (“CD”) plus the applicable goods and services tax (“GST”).  Leases for a second laboratory space for full scale room testing and a storage unit are on a month-to-month basis with a monthly lease payment of CD$1,375 and CD$475, respectively, plus the applicable GST.  

The Company has a corporate office lease arrangement with monthly payments of $2,300 through December 31, 2014.

XML

NOTE 5 COMMITMENTS AND CONTINGENCIES (Details)			12 Months Ended					3 Months Ended				12 Months Ended
	Mar. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2002 Default Judgement [Member] Settlement Amount, January 2002 [Member] Rakas Litigation [Member] USD ($)	Mar. 31, 2014 Default Judgement [Member] Rakas Litigation [Member] USD ($)	Dec. 31, 2013 Default Judgement [Member] Rakas Litigation [Member] USD ($)	Mar. 31, 2014 Litigation Fees [Member] Rakas Litigation [Member] USD ($)	Dec. 31, 2013 Litigation Fees [Member] Rakas Litigation [Member] USD ($)	Mar. 31, 2014 Certified Laboratory Space [Member] CAD	Mar. 31, 2014 Second Laboratory for Full Scale Room Testing [Member] CAD	Mar. 31, 2014 Storage Unit [Member] CAD	Mar. 31, 2014 Corporate Offices [Member] USD ($)	Dec. 31, 2001 Settlement Amount, September 2001 [Member] Rakas Litigation [Member] USD ($)
NOTE 5 COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Litigation Settlement, Amount												$ 25,000
Loss Contingency, Damages Sought, Value			143,000
Accounts Payable, Current	458,299	477,563		143,000	143,000	21,308	21,308
Accounts Payable, Other, Current	224,852	224,852
Operating Leases, Rent Expense, Minimum Rentals								1,375	1,375	475	$ 2,300